Company Long-Term Loans and Borrowings: Theravance (TBPH)

The Theravance Biopharma (TBPH) price chart illustrates the dynamics of a company developing therapies for organs and respiratory tracts, where the indicator stands at 0.06. The business relies on licensing revenue and internal R&D. Steady cash flow is driven by the demand for mature lung products. High barriers to entry are guaranteed by costly research and patents, despite strict FDA oversight.

This indicator aggregates obligations with maturities exceeding one year, measuring the level of long-term credit leverage and debt load risk. The dynamics within the long-term financial debt structure reflect capital sensitivity to new loans, which for Theravance Biopharma (TBPH) is offset by a steady stream of royalties, ensuring high liquidity and resilience to external borrowings.